跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/JPRN-jRCT2041220036
JPRN-jRCT2041220036招募中2 期

Basket study of afatinib maleate (BIBW2992) in patients with solid tumors harboring NRG1 fusion for evaluating efficacy and safety - Alsace trial

Ando Yuichi0 个研究点目标入组 30 人开始时间: 2022年7月1日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
30
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 18age old 至 ot applicable（—）
性别
All

入选标准

  • •1. Patients with advanced solid cancer which has been pathologically diagnosed by the time of consent, have NRG1 fusion gene with preserved EGF-like domain and in refractory or intoletance to standard treatment
  • •2. Patients with a lesion measurable
  • •3. Patients with performance status of 0 to 1 at the time of consent
  • •4. Patients expected to survive for 12 weeks or longer from the initiation day of the treatment
  • •5. Patients whose major organ functions meet the criteria within 28 days before the initiation of administration
  • •6. Patients aged 18 years or more at the time of consent
  • •7. Patients who voluntarily gave written consent after receiving sufficient explanation regarding this clinical trial

排除标准

  • •1. Patients who received the last administration of anticancer drugs (chemotherapy, immunotherapy, biotherapy, etc.) within 21 days before enrollment
  • •2. Patients who have participated in another clinical trial within 21 days before enrollment and within 21 days from last administration of investigational drug on that trial (except for acceptable national trials on authorized indication of disease, dosegae and administration for that investigational drug)
  • •3. Patients with haboring common EGFR mutation (Exon 19 deletion or L858R point mutation)
  • •4. Patients who have history of previous chemotherapy targeting to HER2/HER3
  • •5. Patients whose toxicity due to the previous treatment has not been alleviated to Grade 1 or less severe conditions when assessed according to NCI CTCAE ver. 5.0 (However, patients with Grade 2 or less severe toxicity in stable condition are eligible.)
  • •6. Patients with symptomatic metastasis to the central nervous system (patients with metastasis can be enrolled; if metastasis is asymptomatic, on treatement or local therapy was completed without requirement of increasing dosage of corticosteroid and neurologically stable at leaset 1 week before enrollement)
  • •7. Patients with double cancer with disease-free period less than 1 year (excluding gastrointestinal cancer completely resected by endoscopic mucosal resection, completely resected carcinoma in situ of the cervix, localized or expectively curable prostate cancer, completely resected basal/squamous cell carcinoma of the skin, and other solid tumors similarly expected cure with curable treatment to disease in early disease stage)
  • •8. Patients with active infection requiring systemic administration of antibiotics, antifungal drugs, antiviral drugs, etc.
  • •9. HBs antigen-positive patients
  • •10. Patients complicated with or with a history of interstitial lung disease obvious on images (interstitial pneumonia, pneumonitis, pulmonary fibrosis, etc.)
  • •11. Patients with pleural effusion, pericardial effusion, or ascites that requires drainage (patients with pleural effusion, pericardial effusion, or ascites that has been drained at least 1 week before the enrollment and has not required re-drainage are acceptable)
  • •12. Patients with a clinical symptom or a finding of intestinal obstruction requiring drip infusion or central venous nutrition
  • •13. Patients with a history of serious hypersensitivity or anaphylactic reaction to the components of the investigational product
  • •14. Patients with a serious complication (liver disease [Child Pugh C], renal disease [Ccr is less than 30 mL/min], heart disease, lung disease, blood disease, brain disease, etc.)
  • •15. Female patients who are breast-feeding (excluding those who agree to discontinue breast-feeding during the trial period and for 2 weeks after the last administration of the investigational product)
  • •16. Female patients who are pregnant or tested positive in pregnancy test
  • •17. Male patients or female patients of childbearing potential who are unwilling to use adequate contraception methods during the trial and for 2 weeks after the last administration of the investigational product
  • •18. Other patients who are judged by the investigator or subinvestigator to be inappropriate for participation in this trial

研究者

发起方
Ando Yuichi

相似试验

招募中
不适用
A biomarker analysis of Afatinib treatment in patients with relapse of EGFR-T790M mutation-positive advanced lung adenocarcinoma after 3rd generation EGFR-TKI treatment.EGFR-T790M positive non-small-cell lung cancer relapsed after 3rd generation EGFR-TKI
JPRN-UMIN000025126Kurume University School of Medicine30
进行中（未招募）
2 期
EJ025Bon-sequamous non-small cell lung cancer
JPRN-jRCTs021200005Maemondo Makoto35
进行中（未招募）
1 期
Afatinib and selumetinib in advanced KRAS mutant positive and PIK3CA wildtype non-small cell lung cancer and colorectal cancerPatients with histological or cytological proof of advanced KRAS mutant and PIK3CA wildtype non small cell lung cancer (NSCLC) and colorectal cancer (CRC). In part B: for which first-line treatment failed.MedDRA version: 21.1 Level: PT Classification code 10029520 Term: Non-small cell lung cancer stage IIIA System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10029521 Term: Non-small cell lung cancer stage IIIB System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10029515 Term: Non-small cell lung cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10029518 Term: Non-small cell lung cancer stage II System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2014-001855-22-NLetherlands Cancer Institute- Antoni van Leeuwenhoek Hospital140
进行中（未招募）
1 期
A trial which will look into the effects of giving a drug to patients with non small cell lung cancer with the aim of improving survival outcomes.
EUCTR2011-003608-19-GBniversity College London37
进行中（未招募）
3 期
ACHILLES study/TORG1834Advanced non-small cell lung cancer
JPRN-jRCTs031180175TANAKA Hiroshi106